Portfolio
The Teams We Back
Alpheus Medical
Alpheus Medical is developing an innovative solution to treat aggressive brain tumors using ultrasound delivered via a non-invasive, proprietary device.
Axon Therapies
Axon Therapies is a clinical stage company developing an interventional therapy to treat heart failure, focused initially on the difficult to treat heart failure with preserved ejection fraction.
Cala Health
Cala Health is developing non-invasive wearable neuromodulation therapies, based on recent neuroscience discoveries. The company’s first FDA cleared indication is for the treatment of essential tremor symptoms - learn more about Cala's treatment here.
CVRx (NASDAQ: CVRX)
CVRx has developed BAROSTIM NEO, the world’s first FDA approved neuromodulation therapy for the treatment of heart failure symptoms. CVRx completed a successful IPO in June of 2021.
exo
Exo Imaging is delivering high-performance point-of-care handheld imaging on a proprietary ultrasound-chip platform. Their AI-enabled system aims to globally democratize the access to, and use of diagnostic and therapeutic ultrasound.
MicroTransponder
MicroTransponder®, Inc. is a commercial stage company committed to developing research-based neuroscience solutions. The company focuses on restoring independence and dignity for people suffering from neurological conditions that impair sensory and motor function. MicroTransponder's FDA-approved Vivistim® Paired VNS™ System is a first-of-its-kind, clinically proven therapy that generates two to three times more improvement in upper limb function than rehabilitation alone for stroke survivors – learn more about MicroTransponder’s treatment here.
Neuspera
NeuSpera Medical is a clinical stage company developing minimally invasive neuromodulation therapies using its proprietary MidField Powering technology. The company’s first target-indication is for the treatment of urinary urge incontinence, a symptom of overactive bladder.
Onc AI
Onc.AI is developing a multimodal AI/ML radiomics platform, to support oncologists in personalized therapeutic decision-making for patients across cancer types.
Presidio Medical
Presidio Medical is a clinical-stage company developing a novel, ultra low frequency reversible nerve blocking therapy. The platform technology establishes a new class of therapeutic medical devices to directly treat diseases of undesired neural activity. The company’s initial focus is on treating chronic pain.
Saluda Medical
Saluda Medical is dedicated to improving patients’ lives by providing personalized and responsive neuromodulation therapy. The company has developed Evoke®, the first and only Closed-Loop Spinal Cord Stimulation (SCS) System designed to optimize pain relief by measuring and recording each patient’s unique response to stimulation, and then making millions of real-time adjustments per day to maintain a consistent level of therapy.
SetPoint Medical
SetPoint Medical is a clinical stage company developing a novel and potentially transformative approach to treating autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease, by using miniaturized implantable devices that regulate the body’s inflammatory reflex.